A Study to Evaluate if AC-084 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects
A Three-part Single-center, Phase 1 Study to Assess the Tolerability, Safety, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of Ascending Single and Multiple Doses of AC-084 in Healthy Subjects and to Investigate the Pharmacokinetics of a Single Dose of AC-084 in Healthy CYP2C9 Poor Metabolizers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The study is designed in three parts, A, B and C
Part A: single-center, double-blind, randomized, placebo-controlled, single ascending dose
Part B: single-center, double-blind, randomized, placebo-controlled, multiple ascending dose
Part C: single-center, open-label, single dose in CYP2C9 poor metabolizers
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Leeds, United Kingdom, LS2 9LH
- Covance Clinical Research Unit
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent in the local language prior to any study-mandated procedure
- Healthy male subjects for Part A, healthy male and female subjects for Part B and Part C aged between 18 and 55 years (inclusive) at screening
- No clinically significant findings on physical examination at screening
- Body mass index (BMI) of 18.0 to 28.0 kg/m2 (inclusive) at screening
- CYP2C9 poor metabolizers (Part C)
Exclusion Criteria:
- History or clinical evidence of any disease and/or existence of any surgical or medical condition that might interfere with the absorption, distribution, metabolism or excretion of the study treatment (appendectomy and herniotomy allowed, cholecystectomy not allowed)
- Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions
- Treatment or substances known to induce CYP enzyme drug metabolism within 30 days prior to first study treatment administration
- Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol
- Known allergic reactions or hypersensitivity to the study treatment or drugs of the same class, or any of their excipients
- For Part A and Part B, CYP2C9 poor metabolizers enrolled in a cohort to be dosed with single or multiple dose of 500 mg or higher of ACT-774312 (confirmed by genotyping before enrollment)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: AC-084, single ascending dose (Part A)
AC-084 administered at different single dose levels in a sequential manner, and in a maximum of 7 dose levels starting from 1 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort).
Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
|
Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg
|
|
Placebo Comparator: Placebo,single ascending dose (Part A)
Matched placebo administered as single ascending doses in parallel to AC-084
|
Placebo capsules matching AC-084 capsules
|
|
Experimental: AC-084, multiple ascending dose (Part B)
AC-084 administered in a twice daily (b.i.d.) dosing regimen at multiple dose levels.
The starting dose will be between 1 and 30 mg and will be selected on the basis of the safety and pharmacokinetic results of the part A. Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
|
Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg
|
|
Placebo Comparator: Placebo,multiple ascending dose (Part B)
Matched placebo administered as multiple ascending doses in parallel to AC-084
|
Placebo capsules matching AC-084 capsules
|
|
Experimental: AC-084, single dose (Part C)
Up to 6 subjects in part C will receive AC-084 administered at a single dose (foreseen to be 100 mg)
|
Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with adverse events (AEs) (Part A)
Time Frame: From dosing until day 4
|
Treatment-emergent AEs and treatment-emergent serious AEs
|
From dosing until day 4
|
|
Number of participants with adverse events (AEs) (Part B)
Time Frame: From dosing until day 8
|
Treatment-emergent AEs and treatment-emergent serious AEs
|
From dosing until day 8
|
|
Number of participants with adverse events (AEs) (Part C)
Time Frame: From dosing until day 6
|
Treatment-emergent AEs and treatment-emergent serious AEs
|
From dosing until day 6
|
|
Incidence of safety events of interest (Part A)
Time Frame: From dosing until day 4
|
Events of interest are any abnormalities in ECG, vital signs or laboratory test results
|
From dosing until day 4
|
|
Incidence of safety events of interest (Part B)
Time Frame: From dosing until day 8
|
Events of interest are any abnormalities in ECG, vital signs or laboratory test results
|
From dosing until day 8
|
|
Incidence of safety events of interest (Part C)
Time Frame: From dosing until day 6
|
Events of interest are any abnormalities in ECG, vital signs or laboratory test results
|
From dosing until day 6
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum plasma concentration (Cmax) following single oral ascending doses (Part A)
Time Frame: From dosing until day 4
|
Cmax is derived from the observed plasma concentration-time curves
|
From dosing until day 4
|
|
Maximum plasma concentration (Cmax) following single oral ascending doses (Part B)
Time Frame: From dosing until day 8
|
Cmax is derived from the observed plasma concentration-time curves
|
From dosing until day 8
|
|
Maximum plasma concentration (Cmax) following single oral ascending doses (Part C)
Time Frame: From dosing until day 6
|
Cmax is derived from the observed plasma concentration-time curves
|
From dosing until day 6
|
|
Time to reach Cmax (tmax) following single oral ascending doses (Part A)
Time Frame: From dosing until day 4
|
Tmax is derived from the observed plasma concentration-time curves
|
From dosing until day 4
|
|
Time to reach Cmax (tmax) following single oral ascending doses (Part B)
Time Frame: From dosing until day 8
|
Tmax is derived from the observed plasma concentration-time curves
|
From dosing until day 8
|
|
Time to reach Cmax (tmax) following single oral ascending doses (Part C)
Time Frame: From dosing until day 6
|
Tmax is derived from the observed plasma concentration-time curves
|
From dosing until day 6
|
|
Terminal half-life [t(1/2)] following single oral ascending doses (Part A)
Time Frame: From dosing until day 4
|
From dosing until day 4
|
|
|
Terminal half-life [t(1/2)] following single oral ascending doses (Part B)
Time Frame: From dosing until day 8
|
From dosing until day 8
|
|
|
Terminal half-life [t(1/2)] following single oral ascending doses (Part C)
Time Frame: From dosing until day 6
|
From dosing until day 6
|
|
|
Area under the plasma concentration-time curve (AUC) following single oral ascending doses (Part A)
Time Frame: From dosing until day 4
|
AUC is defined for the time intervals from zero to time t of the last measured concentration above the limit of quantification and from zero to infinity
|
From dosing until day 4
|
|
Area under the plasma concentration-time curve (AUC) following single oral ascending doses (Part B)
Time Frame: From dosing until day 8
|
AUC is defined for the time intervals from zero to time t of the last measured concentration above the limit of quantification and from zero to infinity
|
From dosing until day 8
|
|
Area under the plasma concentration-time curve (AUC) following single oral ascending doses (Part C)
Time Frame: From dosing until day 6
|
AUC is defined for the time intervals from zero to time t of the last measured concentration above the limit of quantification and from zero to infinity
|
From dosing until day 6
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Martine Géhin, PhD, Actelion
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- AC-084-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.